On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The trial sponsor receives blinded reports and data. In a study like psoriasis it is difficult to determine what is normal/natural waxing and waning (placebo effect) and what is due to treatment. But, Leo had raw data.
What I see is every indication for successful outcomes, all outcomes! Please point to any signal for possible failure:
“Cellceutix is encouraged by the interim data from the OM trial (a double blind, placebo controlled study), given the fact that there are no FDA-approved drugs for the prevention of OM in the study population. According to the preliminary interim results from the trial, only 2 of 9 patients (22.2%) on Brilacidin-OM therapy developed severe OM, defined as Grade 3 or Grade 4 on the World Health Organization (WHO) OM Grading Scale. Patients in the placebo-treated control arm developed severe OM at a much higher rate, with 7 of 10 patients (70%) progressing to that condition. There are now an additional 11 patients active in the trial and more are added weekly.”
Your posts are indeed hyperbolic. They do indeed seem designed to raise unreasonable fear. On the one hand they say you think OM will be successful, yet within moments another post states how it is all or none and the dire consequences of failure. It’s a contradiction. Contradiction is not fair and balanced if it fails to outline the elements of failure and the real chances of such failure. Knowing the results of interim data, highly successful results (not just signals), why are the posts putting such high emphasis on failure? Repeatedly!
Thanks, tryz
Thanks and thanks!
My understanding is there are no trading halts on the OTC. Someone else can confirm this if it’s still the case.
Well, hopefully the Moon is also just another step on the way to Venus, or even Mars.
This an excellent positive consolidation: up several cents from yesterday’s close, but inside the candle’s long wick. Frankly I’d like to see it take today, tomorrow and Monday to engulf that wick then followed immediately by news (OM, of course). On the 10 minute chart that would complete a cup and handle, but that handle would look like that of a long-handled ladle. A very long-handled ladle, stretching to the moon, or $2, which ever is closer.
Yikes is right. Either this is burning shorts, short squeeze like fruit through a juicer, or something more than top line data is in the works.
Bids now stacked 50k deep at 1.15. 1.16 is thin.
And, there’s 1.10.
Exactly the same thing you said yesterday and the day before just before a tiny dip and a move higher. Thank you.
looks like a blow off top
“How many times have you said that this week? If I had a nickel for every time you said that...”
You’d have enough to buy 5 more shares?
I have been averaging up for 2 weeks by buying dips. No joke, every time he has said down we go, I’ve filled my bid two to 3 cents lower than his call and ahead of the bounce to the next level up. Today I bid .98 when .99 was filling, he said brick wall and going lower, my bid filled at .96. Really happened.
Not that I’m advising anyone to do this, but he has been a great contrary signal for these past 3 weeks.
Your original post implied it was shelved. I was pointing out that OC results are soon and in the Phase 1 trial had the strongest efficacy signals at only once a week. That’s data and results
Regarding Kevetrin, 6 words:
Ovarian Cancer, Ovarian Cancer, Ovarian Cancer
I remember those. Great early call.
From what I see, we will be waving through the window at 51.53 as we drive by it. No failures, if that continues....
Yes, we did. Many of us called those .60s. But I’m in an IPIX best call pissing contest.
I’ve now shifted to averaging up. So far it’s worked out fine. But eventually some shares will be bought too high for the moment and I’ll get caught in a correction, temporarily. Nature of the beast.
The wall of .92s are gone and .93 is up with10k on ask. .92 is now bid with about 1100 shares. The 50k bid at .91 is still there. Hmmm indeed.
Um, you basically told people not to buy at .67 the day before I correctly called the bottom? OK.
Mouthwash is a topical application provided there is little to no absorption and systemic exposure. It all depends on how the FDA reads the very low blood levels of Brilacidin that enter circulation. Possible, but it’s not something I would speculate on. The FDA can be a little arbitrary.
Yep. Called the bottom, again. Won’t call a top for a while longer.
Been watching that chipping away at .92. Only 5k left (according to Scottrade). Very little dropping into the bid. Still over 50k at .91. My 88. Might turn out to be a stink bid instead of a interday correction.
Here’s one I posted back in October when others were still trash talking. My 247 “subscribers” are now up 50% since I made this call. How did your 50 “subscribers” do since the weekend and during an already 1 month established bull run?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135455373
Scottrade shows 53k on the bid @ .91. A real battle mounting here. Bid is double the ask at 91/92.
.90-1.08 before or after OM data?
That’s hilarious.
Bullshit.
No you’ve never heard this before because the events beginning this next week have never happened before. None of what is about to happen has ever happened before.
That’s part of the paradigm shift. B-OM news will drive the price because it will cause anticipation buying for a partnership to take place in the first or early second quarter. In the meantime, there will br K-OM and Prurisol top-line data that will add support for the 6 month bull run following any results in the neighborhood of the interim data.
Sorry, but expecting Aspire selling, you are on the short end of that big stick. No trials are planned until a partnership is inked or Leo absolutely has to. Leo controls Aspire buying and indirectly Aspire selling. No forced Aspire buys, no or limited Aspire selling.
The above are all elements in the still larger paradigm shift.
The anticipated news will cause a paradigm shift. Sell the news if you want to leave another 500% gain on the table. Short it if you are suicidal. If it’s not what we anticipate, you won’t be able to sell fast enough. So, sell tomorrow and just get it over with. It’ll be the last nickel flip for a long while.
I don’t think that’s what he said at all. He’s saying there is almost no downside risk right now.
Under $2 gives tremendous leverage on the eventual share price which I see as anywhere from $10 on up. (Emphasis on “on up.”) That would be 5 for 1 minimum, a lot like buying options ahead of a major deal ( but with less downside risk and no expiration.
So, you are already out on the trade with OM results coming within the week? Wow.
...maybe buy some there
Yes, if I also understood it correctly. But, the placebo incidence should be above 80%, so there is a larger potential for a larger spread.
This week or next we are likely to get top line results. If the outcomes reflect those of the interim report, someone will be partnering and it is likely one of those someones will be looking for the entire B platform. The only question to me is whether or not that BP will pony up what the platform is worth after 1 successful PoC trial, 1 successful powered PoC trial, and 1 successfully completed Phase 2 trial.
For B-OM only, what is the value with a >30% spread between the primary outcomes for placebo vs. B? Well, 50% of +300K annual cases in the US alone (exclusivity for the only effective treatment), times $5K per treatment course, yields $750 million gross annual sales. Anyone have a similar example of a deal struck for a first in class?
I think he means the spread between the placebo group and the Brilacidin rinse for the primary outcome: Incidence of severe oral mucositis (WHO Grade ≥3).
“According to CEO Leo Ehrlich, that study will be un-blinded and top-line data will be released in about a week.“
That’s not exactly saying “next week” now is it. Like I said, artificial deadlines designed to create binary events out of thin air.
What part of in the next week or so makes you convinced that this is a binary week? What if data isn’t ready until Thursday and Leo decides it’s better to wait for the release until early next week? I mean WTF? This artificial deadline is exactly the shit that pisses so many of us off.